Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 8
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Chen, W. and Krahn, M. 2015. Disease burden of chronic hepatitis C among immigrants in Canada. Journal of Viral Hepatitis, Vol. 22, Issue. 12, p. 1043.

    Gelband, Hellen Chen, Chien-Jen Chen, Wendong Franceschi, Silvia Hall, Sir Andrew London, W. Thomas McGlynn, Katherine A. and Wild, Christopher P. 2015. Disease Control Priorities, Third Edition (Volume 3): Cancer.

    Daw, Mohamed A Elasifer, Hana A Dau, Aghnaya A and Agnan, Mohamed 2013. The role of hepatitis C virus genotyping in evaluating the efficacy of INF-based therapy used in treating hepatitis C infected patients in Libya. Virology Discovery, Vol. 1, Issue. 1, p. 3.

    de Mora, Fernando and Torres, Rosa 2010. Biotechnology-derived medicines: What are they? A pharmacological and a historical perspective. Journal of Generic Medicines, Vol. 7, Issue. 2, p. 145.

    Mori, Nobuhiro Yokooji, Tomoharu Kamio, Yoshihiro and Murakami, Teruo 2010. Study on intestinal absorption sites of mizoribine and ribavirin, substrates for concentrative nucleoside transporter(s), in rats. European Journal of Pharmacology, Vol. 628, Issue. 1-3, p. 214.

    Weclawiak, Hugo Kamar, Nassim Ould-Mohamed, Abdellatif Cardeau-Desangles, Isabelle Izopet, Jacques and Rostaing, Lionel 2010. Treatment of Chronic Hepatitis C Virus Infection in Dialysis Patients: An Update. Hepatitis Research and Treatment, Vol. 2010, p. 1.

    Kristensen, Finn Børlum Lampe, Kristian Chase, Deborah L. Lee-Robin, Sun Hae Wild, Claudia Moharra, Montse Garrido, Marcial Velasco Nielsen, Camilla Palmhøj Røttingen, John-Arne Neikter, Susanna Allgurin and Bistrup, Marie Louise 2009. Practical tools and methods for health technology assessment in Europe: Structures, methodologies, and tools developed by the European network for Health Technology Assessment, EUnetHTA. International Journal of Technology Assessment in Health Care, Vol. 25, Issue. S2, p. 1.

    Quentin, Fabienne Carbonneil, Cédric Moty-Monnereau, Céline Berti, Elena Goettsch, Wim and Lee-Robin, Sun Hae 2009. Web-based toolkit to facilitate European collaboration on evidence generation on promising health technologies. International Journal of Technology Assessment in Health Care, Vol. 25, Issue. S2, p. 68.

  • International Journal of Technology Assessment in Health Care, Volume 25, Issue 1
  • January 2009, pp. 56-62

Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and meta-analysis

  • Debbie Hartwell (a1) and Jonathan Shepherd (a1)
  • DOI:
  • Published online: 01 January 2009

Objectives: Traditionally, patients with chronic hepatitis C virus (HCV) infection have not received treatment until their infection reaches the moderate to severe stage. The aim of this systematic review was to assess the clinical effectiveness of pegylated (PEG) and non-pegylated interferon (IFN) alfa and ribavirin (RBV) for the treatment of adults with histologically mild HCV.

Methods: We performed a sensitive search of fourteen electronic bibliographic databases for literature that met criteria defined in a research protocol. Two reviewers independently selected studies, extracted data and assessed methodological quality.

Results: Ten randomized, controlled trials (RCTs) were included. Treatment with PEG + RBV combination therapy resulted in significantly higher sustained virological response (SVR) rates than treatment with IFN + RBV combination therapy. Treatment for 48 weeks with PEG + RBV was significantly more effective than the same treatment for 24 weeks. Significantly higher SVR rates were seen with IFN + RBV compared with either IFN monotherapy or no treatment. In the meta-analysis (four IFN trials), the relative risk of not experiencing an SVR was 0.59 (95 percent CI, 0.51 – 0.69) and was statistically significant (p < .00001). SVRs were higher for patients with genotype non-1 compared with genotype 1 for both PEG + RBV and IFN + RBV treatments.

Conclusions: Patients with histologically mild HCV can be successfully treated with both PEG and IFN combination therapy, and response rates are broadly comparable with those achieved in patients with advanced disease. Treating patients in the early milder stages of HCV is, therefore, a clinically effective option.

Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1.S Arora , C O'Brien , S Zeuzem , Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: Impact on health-related quality of life. J Gastroenterol Hepatol. 2006;21:406412.

2.CM Behler , E Vittinghoff , F Lin , Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Clin Infect Dis. 2007;44:13751383.

3.PN Cheng , NH Chow , SC Hu , Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C. Dig Liver Dis. 2002;34:851856.

4.RT Chung , J Andersen , P Volberding , Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451459.

6.GR Foster , RD Goldin , HC Thomas . Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27:209212.

7.SJ Hadziyannis , H Jr Sette , TR Morgan , et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346355.

8.KA Harris , C Gilham , PP Mortimer , The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol. 1999;58:127131.

9.TH Kim , KA Kim , YS Lim , Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy. Intervirology 2005;48:230238.

10.A Mangia , MR Villani , N Minerva , Efficacy of 5 MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus: A randomized controlled trial. J Hepatol. 2001;34:441446.

11.D Moher , DJ Cook , S Eastwood , et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Lancet. 1999;354:18961900.

12.AH Mohsen , HCV Trent Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut. 2001;48:707713.

16.T Poynard , J McHutchison , Z Goodman , Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 2000;31:211218.

17.O Reichard , G Norkrans , A Fryden , Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998;351:8387.

18.SD Ryder , WL Irving , DA Jones , Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut. 2004;53:451455.

19.J Shepherd , H Brodin , C Cave , Pegylated interferon a-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess. 2004;8:1140.

20.J Shepherd , J Jones , D Hartwell , Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess. 2007;11:1205.

21.DB Strader , T Wright , DL Thomas American Association for the Study of Liver Diseases (AASLD) practice guidelines. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:11471171.

22.HP Verbaan , HE Widell , TL Bondeson , High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin. Eur J Gastroenterol Hepatol. 2002;14:627633.

23.M von Wagner , M Huber , T Berg , Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129:522527.

24.M Wright , D Forton , J Main , Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: A multicentre randomized controlled trial. J Viral Hepat. 2005;12:5866.

25.S Zeuzem , M Diago , E Gane , Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004;127:17241732.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Type Description Title
Supplementary Materials

Hartwell supplementary tables
Hartwell supplementary tables

 Unknown (404 KB)
404 KB